Login to Your Account



Theravance, Mylan herald positive top-line results in two phase III COPD studies

By Michael Fitzhugh
Staff Writer

Thursday, October 20, 2016

Theravance Biopharma Inc. and Mylan NV reported that revefenacin, a nebulized LAMA for COPD, met the primary endpoints in twin phase III studies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription